TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth

@article{Inoki2006TSC2IW,
  title={TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth},
  author={Ken Inoki and Hongjia Ouyang and Tianqing Zhu and Charlotta Lindvall and Yian Wang and Xiaojie Zhang and Qian Yang and Christina N. Bennett and Yuko Harada and Kryn Stankunas and Cun-Yu Wang and Xi He and Ormond A. MacDougald and Ming You and Bart O. Williams and Kun Liang Guan},
  journal={Cell},
  year={2006},
  volume={126},
  pages={955-968}
}
View on Elsevier
cell.com
1,245 Citations
Highly Influential Citations
102
Background Citations
562
Methods Citations
11
Results Citations
13

Figures from this paper

1,245 Citations

Citation Type

Citation Type

Consequences of interrupted Rheb-to-AMPK feedback signaling in tuberous sclerosis complex and cancer
TLDR
How Rheb-to-AMPK, and p27 signaling may impact on disease progression and treatment of TSC, including sporadic lymphangioleio-myomatosis (S-LAM) and malignancies is discussed.
TSC1/TSC2 inactivation inhibits AKT through mTORC1-dependent up-regulation of STAT3-PTEN cascade.
PKG-Modified TSC2 Regulates mTORC1 Activity to Counter Adverse Cardiac Stress
TLDR
It is shown that phosphorylation or gain- or loss-of-function mutations at either of two adjacent serine residues in TSC2 can bidirectionally control mTORC1 activity stimulated by growth factors or haemodynamic stress, and consequently modulate cell growth and autophagy.
Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth.
TLDR
A novel mechanism by which mTORC2 promotes cell growth is defined, with potential implications for understanding the clinical action of mTOR kinase inhibitors, which are being evaluated in cancer clinical trials.
IKKβ Suppression of TSC1 Links Inflammation and Tumor Angiogenesis via the mTOR Pathway
Growth factor signaling pathways converge on the TSC complex to control mTOR
TLDR
The goals of this dissertation were to characterize the mechanisms by which upstream growth factor signaling pathways converge on the TSC complex to activate mTORC1, and to determine the significance of these mechanisms in disease and to gain more mechanistic details surrounding this regulation.
Crosstalk between mTORC1 and cAMP Signaling
TLDR
It is shown that mTORC1 is potently inhibited by hormones that stimulating cAMP, and the data indicate that cAMP acts through protein kinase A (PKA) to inhibit m TORC1.
IKBKE inhibits TSC1 to activate the mTOR/S6K pathway for oncogenic transformation.
  • S. Göktuna
  • Biology
    Turkish journal of biology = Turk biyoloji dergisi
  • 2018
TLDR
This work proposes a mechanism where IKKε, through regulating TSC1 stability in cancer cells, may create an alternative regulatory loop for the activation of mTOR signaling, and results can potentially be important for the development of novel therapeutic strategies targeting m TOR signaling.
Regulation of the Mammalian Target Of Rapamycin Complex 2 (mTORC2)
TLDR
The results suggest that mTORC2 hyperactivation may contribute to the pathophysiology of diseases such as cancer and Tuberous Sclerosis Complex.
Repression of the protein kinase PIM3 by an mTORC1-regulated microRNA
TLDR
PIM inhibition in combination with mTOR inhibitors may be a promising therapy in some cancer settings, and it is shown that PIM3 repression is mediated by miR-33, an intronic microRNA encoded within the SREBP loci, the expression of which is decreased with rapamycin.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 67 REFERENCES
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis
Aberrant β-Catenin Signaling in Tuberous Sclerosis
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
TLDR
A regulatory mechanism by which the Ras/MAPK and PI3K pathways converge on the tumor suppressor tuberin to inhibit its function is unveiled.
Aberrant beta-catenin signaling in tuberous sclerosis.
TLDR
It is shown that beta-catenin and its effectors, cyclin D1 and connexin 43, were up-regulated in TSC-related angiomyolipomas and lymphangioleiomyomatosis and a novel role of GSK3 in modulating the T SC1/TSC2 complex through TSC1 phosphorylation is suggested.
Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex
TLDR
It is shown that in Drosophila and human cells the target of rapamycin (TOR) kinase and its associated protein rictor are necessary for Ser473 phosphorylation and that a reduction in rictOr or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.
Rheb promotes cell growth as a component of the insulin/TOR signalling network
TLDR
Genetic and biochemical tests indicate that Rheb functions in the insulin signalling pathway downstream of Tsc1–Tsc2 and upstream of TOR, suggesting a role for rheb in the nutritional control of cell growth.
Tsc tumour suppressor proteins antagonize amino-acid–TOR signalling
TLDR
These studies identify Tsc1 and Tsc2 as regulators of the amino acid–TOR pathway and provide a new paradigm for how proteins involved in nutrient sensing function as tumour suppressors.
The Tuberin-Hamartin Complex Negatively Regulates β-Catenin Signaling Activity*
TLDR
The data suggest that hamartin and tuberin negatively regulate β-catenin stability and activity by participating in the β-Catenin degradation complex.
The tuberin-hamartin complex negatively regulates beta-catenin signaling activity.
TLDR
The data suggest that hamartin and tuberin negatively regulate beta-Catenin stability and activity by participating in the beta-catenin degradation complex.
...
1
2
3
4
5
...